Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 763


Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.


PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.

Kim J, Guan J, Chang I, Chen X, Han D, Wang CY.

Mol Cancer Ther. 2010 Jul;9(7):1977-84. doi: 10.1158/1535-7163.MCT-10-0141. Epub 2010 Jun 22.


Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. Epub 2005 Jul 11.


Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.

Br J Haematol. 2011 Apr;153(2):222-35. doi: 10.1111/j.1365-2141.2011.08591.x. Epub 2011 Mar 6.


Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.


Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.

Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470.


Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer.

Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C.

Clin Cancer Res. 2009 Oct 1;15(19):5974-84. doi: 10.1158/1078-0432.CCR-09-1352. Epub 2009 Sep 29.


A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.

Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, Chen Z.

Int J Cancer. 2008 May 1;122(9):1987-98. doi: 10.1002/ijc.23324.


Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368. Epub 2011 Jan 11.


Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.

J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. Epub 2006 Jul 18.


Supplemental Content

Support Center